Precigen, Inc. · NASDAQ:PGEN
Precigen — Q1 2020 Earnings Presentation
14 slides from Precigen's earnings presentation, May 6, 2020
Slide 1: Precigen, Inc. 1Q-2020 Business Update
Precigen, Inc. 1Q-2020 Business Update 6 May 2020 Exhibit 99.2
Slide 2: Forward-looking Statements
Forward-looking Statements Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon Precigen's current expectations and projecti
Slide 3: Adhering to Operating Principles to Deliver Value to All Stakeholders
Adhering to Operating Principles to Deliver Value to All Stakeholders PRECIGEN’S VISION FOR PATIENTS Develop life-saving and cost-conscious therapies utilizing our cutting-edge platform technologies for patients with unmet need FISCAL STRENGTH Responsible capital allocation to ensure runway for maxi
Slide 4: One Precigen: Deploying Novel Approaches to Address Unmet Healthcare Needs
One Precigen: Deploying Novel Approaches to Address Unmet Healthcare Needs Therapeutic gene(s) inserted Non-viral multi-gene delivery Non-exhausted, stem-like T cell phenotype Higher antigen-specific expansion Enhanced in vivo persistence Ability to deplete with kill switch Overnight manufacturing p
Slide 5: Our Non-Healthcare Asset Strategy
Our Non-Healthcare Asset Strategy MBP Titan Significantly reduced cash requirement Steps to secure IP and technology Support partnering discussions Trans Ova Genetics Increase operational efficiencies On-track to contribute cash to Precigen Continue to evaluate strategic alternatives
Slide 6: Robust Pipeline with Many Milestones to Drive Value
PRODUCT PLATFORM INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MILESTONES AG019 ActoBiotics Type 1 Diabetes Interim data 3Q20 PRGN-3005 UltraCAR-T Ovarian Cancer Initial data 2H20 PRGN-3006 UltraCAR-T AML, MDS Initial data in 2H20 INXN-4001 Non-viral UltraVector Heart Failure Top line dat
Slide 7: PRGN-2009, a first-in-class off-the-shelf AdenoVerse immunotherapy for HPV+ cancers
PRGN-2009, a first-in-class off-the-shelf AdenoVerse™ immunotherapy for HPV+ cancers PRGN-2009 AdenoVerse Immunotherapy IND to initiate Phase 1/2 trial cleared by the FDA Phase 1 to evaluate safety and response in patients with HPV-associated cancers Gorilla adenoviral vector with ability for repeat
Slide 8: PRGN-2009 AdenoVerse Immunotherapy: Phase 1 trial design
PRGN-2009 AdenoVerse Immunotherapy: Phase 1 trial design Phase 1 study will evaluate safety and response of PRGN-2009 alone and in combination with M7824 (bintrafusp alfa) in patients with HPV-associated cancers Clinical development under CRADA with NCI Dr. Julius Strauss as Principal Investigator A
Slide 9: PRGN-3005, a first-in-class therapy in ovarian cancer
PRGN-3005, a first-in-class therapy in ovarian cancer Phase 1 trial is ongoing Arm A: Intraperitoneal (IP) infusion; Arm B: Intravenous (IV) infusion Dosing in Dose Level 2 of IP arm completed 100% manufacturing success to date Encouraging preliminary findings of UltraCAR-T kinetics Initial data rea
Slide 10: Our UltraCAR-T Platform Promises a More Effective Way to Treat Patients
Our UltraCAR-T® Platform Promises a More Effective Way to Treat Patients Reliance on viral vectors Complexity of manufacturing viral vectors Long and complex CAR-T cell manufacturing process Long delays for patients High cost of manufacturing Exhausted T cell phenotype Major challenges in solid tumo
Slide 11: PRGN-3006, a first-in-class therapy in AML
PRGN-3006, a first-in-class therapy in AML Phase 1/1b trial is ongoing Arm 1: No Lymphodepletion; Arm 2: With Lymphodepletion Enrolling patients in Arm 1 and Arm 2 concurrently 100% manufacturing success to date Encouraging preliminary findings of UltraCAR-T kinetics Initial data readout expected in
Slide 12: Robust Pipeline with Many Milestones to Drive Value
PRODUCT PLATFORM INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MILESTONES AG019 ActoBiotics Type 1 Diabetes Interim data 3Q20 PRGN-3005 UltraCAR-T Ovarian Cancer Initial data 2H20 PRGN-3006 UltraCAR-T AML, MDS Initial data in 2H20 INXN-4001 Non-viral UltraVector Heart Failure Top line dat
Slide 13: Upcoming 2020 Clinical Milestones
Upcoming 2020 Clinical Milestones Initial data from IP arm of PRGN-3005 UltraCAR-T Phase 1 trial in Ovarian Cancer Initial data from PRGN-3006 UltraCAR-T Phase 1 trial in AML and MDS Interim data from Phase 1b/2a trial of AG019 in Type 1 Diabetes Top line data from Phase 1 trial of INXN-4001 in Hear
Slide 14: Precigen: Advancing Medicine with Precision
G PRECIGEN ADVANCING MEDICINE WITH PRECISION™ We Ga my